Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samarium Sm 153 Lexidronam in Relapsed/Refractory Multiple Myeloma
NCT00482378Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of samarium-153 lexidronam in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoints: Safety and tolerability of samarium Sm 153 lexidronam pentasodium in combination with zoledronic acid or pamidronate disodium at 12 weeks and Confirmed clinical response of serum and urine monoclonal protein at 12 weeks. Started Mar 2005; status: completed.
02
Drugs
samarium-153 lexidronam
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00482378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482378.